Search alternatives:
latest decrease » largest decrease (Expand Search), greatest decrease (Expand Search), largest decreases (Expand Search)
small decrease » small increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a latest » a latent (Expand Search), _ latest (Expand Search), _ latent (Expand Search)
latest decrease » largest decrease (Expand Search), greatest decrease (Expand Search), largest decreases (Expand Search)
small decrease » small increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a latest » a latent (Expand Search), _ latest (Expand Search), _ latent (Expand Search)
-
1
-
2
-
3
Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc
Published 2025“…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20